Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$0.01
$0.02
$0.01
$0.02
$147K0.7418,907 shs7,027 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.00
-10.2%
$4.63
$1.04
$7.25
$44.88M-0.39868,143 shs66,186 shs
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$0.07
$0.01
$0.01
$726K1.632.58 million shs2.48 million shs
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
$10.50
$0.37
$12.58
$2.56B0.831.07 million shs93,330 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.23
-1.2%
$1.18
$0.90
$1.88
$14.33M0.5516,858 shs2,054 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00%0.00%0.00%0.00%-76.47%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
+8.09%+6.03%-39.38%-17.73%+133.57%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
0.00%0.00%0.00%0.00%0.00%
Synlogic, Inc. stock logo
SYBX
Synlogic
-1.53%+2.09%-4.24%+20.30%-16.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.6283 of 5 stars
0.03.00.00.02.21.70.0
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.4236 of 5 stars
0.03.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00
N/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00
N/AN/AN/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
0.00
N/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$5.64M0.03N/AN/A$0.27 per share0.04
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$41.08M1.16$0.27 per share11.99$1.61 per share1.98
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$2.59M0.00N/AN/A($0.21) per share0.00
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
$40M0.00N/A3.39$0.78 per share0.00
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,416.87N/AN/A$1.09 per share1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
-$19.83M-$0.84N/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$6.48M-$0.25N/AN/A-7.98%6.92%2.33%8/5/2025 (Estimated)
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/6/2025 (Estimated)

Latest SYBX, BLPH, CPIX, INFI, and SESN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A$0.15N/A$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.18
1.25
1.09
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/A
1.65
1.65
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/A
6.10
6.10
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.68
3.68

Institutional Ownership

CompanyInstitutional Ownership
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
10.61%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
22.14%
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
16.45%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
2012.23 million11.60 millionNo Data
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.96 million8.25 millionOptionable
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
3090.76 million81.86 millionOptionable
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
35203.49 million196.98 millionOptionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bellerophon Therapeutics stock logo

Bellerophon Therapeutics NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.00 -0.34 (-10.18%)
Closing price 04:00 PM Eastern
Extended Trading
$3.03 +0.03 (+1.00%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Infinity Pharmaceuticals stock logo

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Sesen Bio stock logo

Sesen Bio NASDAQ:SESN

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.23 -0.01 (-0.48%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.